- 1,166
Overall, these top 25 drugs were responsible for nearly $50 billion in total Medicare Part D spending in 2022, AARP finds.
The brand-name drugs covered under Medicare Part D have nearly doubled in price, and 25 of them are now up 98% since they debuted in the market, a new AARP Public Policy Institute analysis has found.
These lifetime price increases often greatly exceeded the corresponding rate of general inflation, AARP found.
The analysis also found that, on average, more than 40% of the current list prices for the top 25 drugs is due to price increases that have occurred since the products first entered the market.
All of the data was based on the 25 brand-name drugs with the highest total Medicare Part D spending in 2022 that have not yet been selected for Medicare drug price negotiation, as reported in the Medicare Part D Spending by Drug Dashboard.
Overall, these top 25 drugs were responsible for nearly $50 billion in total Medicare Part D spending in 2022 and were used by a total of more than 7 million Part D enrollees, according to AARP.
The 25 drugs include Trulicity, Ozempic, Trelegy Ellipta, Biktarvy, Xtandi, Humalog, Ibrance, Jakafi, Ofev, Pomalyst, Levemir, Tresiba, Linzess, Victoza, Breo Ellipta, Tradjenta, Creon, Ingrezza, Janumet, Calquence, Tagrisso, Epclusa, Xifaxan, Vyndamax and Cabometyx.
[EXTERNAL LINK] - Medicare Part D drug prices up nearly 100%
